Skip to main content

Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial.

Publication ,  Journal Article
Murphy, AB; Abern, MR; Liu, L; Wang, H; Hollowell, CMP; Sharifi, R; Vidal, P; Kajdacsy-Balla, A; Sekosan, M; Ferrer, K; Wu, S; Gallegos, M ...
Published in: J Clin Oncol
May 20, 2021

PURPOSE: The Genomic Prostate Score (GPS), performed on biopsy tissue, predicts adverse outcome in prostate cancer (PCa) and has shown promise for improving patient selection for active surveillance (AS). However, its impact on treatment choice in high-risk populations of African Americans is largely unknown and, in general, the effect of the GPS on this difficult decision has not been evaluated in randomized trials. METHODS: Two hundred men with National Comprehensive Cancer Network very low to low-intermediate PCa from three Chicago hospitals (70% Black, 16% college graduates) were randomly assigned at diagnosis to standard counseling with or without a 12-gene GPS assay. The primary end point was treatment choice at a second postdiagnosis visit. The proportion of patients choosing AS was compared, and multivariable modeling was used to estimate the effects of various factors on AS acceptance. RESULTS: AS acceptance was high overall, although marginally lower in the intervention group (77% v 88%; P = .067), and lower still when men with inadequate specimens were excluded (P = .029). Men with lower health literacy who received a GPS were seven-fold less likely to choose AS compared with controls, whereas no difference was seen in men with higher health literacy (Pinteraction = .022). Among men with low-intermediate risk, 69% had GPS values consistent with unfavorable intermediate or high-risk cancer. AS choice was also independently associated with a family history of PCa and having health insurance. CONCLUSION: In contrast to other studies, the net effect of the GPS was to move patients away from AS, primarily among men with low health literacy. These findings have implications for our understanding of how prognostic molecular assays that generate probabilities of poor outcome can affect treatment decisions in diverse clinical populations.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

May 20, 2021

Volume

39

Issue

15

Start / End Page

1660 / 1670

Location

United States

Related Subject Headings

  • Risk Factors
  • Oncology & Carcinogenesis
  • Male
  • Humans
  • Genomics
  • Black or African American
  • Aged
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Murphy, A. B., Abern, M. R., Liu, L., Wang, H., Hollowell, C. M. P., Sharifi, R., … Gann, P. H. (2021). Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial. J Clin Oncol, 39(15), 1660–1670. https://doi.org/10.1200/JCO.20.02997
Murphy, Adam B., Michael R. Abern, Li Liu, Heidy Wang, Courtney M. P. Hollowell, Roohollah Sharifi, Patricia Vidal, et al. “Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial.J Clin Oncol 39, no. 15 (May 20, 2021): 1660–70. https://doi.org/10.1200/JCO.20.02997.
Murphy AB, Abern MR, Liu L, Wang H, Hollowell CMP, Sharifi R, et al. Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial. J Clin Oncol. 2021 May 20;39(15):1660–70.
Murphy, Adam B., et al. “Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial.J Clin Oncol, vol. 39, no. 15, May 2021, pp. 1660–70. Pubmed, doi:10.1200/JCO.20.02997.
Murphy AB, Abern MR, Liu L, Wang H, Hollowell CMP, Sharifi R, Vidal P, Kajdacsy-Balla A, Sekosan M, Ferrer K, Wu S, Gallegos M, King-Lee P, Sharp LK, Ferrans CE, Gann PH. Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial. J Clin Oncol. 2021 May 20;39(15):1660–1670.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

May 20, 2021

Volume

39

Issue

15

Start / End Page

1660 / 1670

Location

United States

Related Subject Headings

  • Risk Factors
  • Oncology & Carcinogenesis
  • Male
  • Humans
  • Genomics
  • Black or African American
  • Aged
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences